{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-034095","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.674684+00:00","generated_at":"2026-05-16T22:12:37.450305+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CervoMed reports Q3 2025 net loss $7.7M; FDA aligned on Phase 3 trial design for neflamapimod in DLB","bullets":["Net loss of $7.7M for Q3 2025 vs $4.8M in Q3 2024; cash $27.3M at Sept 30, 2025.","FDA alignment on design of planned Phase 3 trial of neflamapimod for dementia with Lewy bodies; global pivotal trial initiation targeted H2 2026.","Phase 2b RewinD-LB 32-week data showed 64% risk reduction in clinically significant worsening on CDR-SB (p<0.001) in DLB patients with low AD co-pathology.","R&D expenses $6.0M (up $0.9M YoY) primarily due to increased personnel and CMC activities; G&A $2.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-034095","json":"https://secwatch.observer/filing/0001437749-25-034095.json","markdown":"https://secwatch.observer/filing/0001437749-25-034095.md","text":"https://secwatch.observer/filing/0001437749-25-034095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925034095/0001437749-25-034095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925034095/crvo20251110_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:12:37.450305+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}